Emergent Biosolutions Price to Book Ratio 2007-2021 | EBS

Historical price to book ratio values for Emergent Biosolutions (EBS) over the last 10 years. The current price to book ratio for Emergent Biosolutions as of December 07, 2021 is 1.49.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Emergent Biosolutions Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-12-06 41.99 1.48
2021-09-30 50.07 $28.36 1.77
2021-06-30 62.99 $28.75 2.19
2021-03-31 92.91 $28.41 3.27
2020-12-31 89.60 $27.30 3.28
2020-09-30 103.33 $23.61 4.38
2020-06-30 79.08 $22.66 3.49
2020-03-31 57.86 $20.55 2.82
2019-12-31 53.95 $21.05 2.56
2019-09-30 52.28 $20.06 2.61
2019-06-30 48.31 $19.16 2.52
2019-03-31 50.52 $19.21 2.63
2018-12-31 59.28 $19.74 3.00
2018-09-30 65.83 $19.26 3.42
2018-06-30 50.49 $18.76 2.69
2018-03-31 52.65 $17.69 2.98
2017-12-31 46.47 $18.47 2.52
2017-09-30 40.45 $16.04 2.52
2017-06-30 33.91 $15.10 2.25
2017-03-31 29.04 $14.90 1.95
2016-12-31 32.84 $14.69 2.23
2016-09-30 31.53 $13.53 2.33
2016-06-30 26.35 $16.64 1.58
2016-03-31 34.06 $16.74 2.03
2015-12-31 37.49 $16.75 2.24
2015-09-30 26.70 $15.57 1.71
2015-06-30 30.88 $14.51 2.13
2015-03-31 26.95 $14.03 1.92
2014-12-31 25.52 $14.67 1.74
2014-09-30 19.97 $13.67 1.46
2014-06-30 21.05 $13.02 1.62
2014-03-31 23.68 $12.80 1.85
2013-12-31 21.54 $13.36 1.61
2013-09-30 17.85 $12.86 1.39
2013-06-30 13.51 $12.41 1.09
2013-03-31 13.10 $12.07 1.09
2012-12-31 15.03 $12.33 1.22
2012-09-30 13.32 $11.85 1.12
2012-06-30 14.20 $11.67 1.22
2012-03-31 14.99 $11.40 1.32
2011-12-31 15.78 $11.57 1.36
2011-09-30 14.46 $10.72 1.35
2011-06-30 21.13 $10.63 1.99
2011-03-31 22.64 $10.13 2.23
2010-12-31 21.98 $10.67 2.06
2010-09-30 16.17 $8.90 1.82
2010-06-30 15.31 $8.40 1.82
2010-03-31 15.73 $8.04 1.96
2009-12-31 12.73 $7.91 1.61
2009-09-30 16.55 $7.71 2.15
2009-06-30 13.43 $7.60 1.77
2009-03-31 12.66 $7.04 1.80
2008-12-31 24.47 $6.61 3.70
2008-09-30 12.27 $6.46 1.90
2008-06-30 9.30 $6.08 1.53
2008-03-31 8.36 $6.00 1.39
2007-12-31 4.74 $5.75 0.82
2007-09-30 8.32 $4.82 1.73
2007-06-30 9.65 $4.71 2.05
2007-03-31 12.58 $4.92 2.55
2006-12-31 10.46 $5.02 2.08
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.270B $1.555B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $6.887B 0.00
Arcus Biosciences (RCUS) United States $3.210B 0.00
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.469B 0.00
Zymeworks (ZYME) Canada $0.850B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Ambrx Biopharma (AMAM) United States $0.322B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71